Investigate the effects of Pomegranate Extract Supplementation on Inflammation in Overweight and Obese Individuals
- Conditions
- Overweight and obesity.Simple obesity NOS
- Registration Number
- IRCT2015062722934N1
- Lead Sponsor
- Vice Chancellor for research of Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria: Willingness to participation; Between the age 30-60 years old and Having a BMI within the range 25-40 kgm2; does not have a history of use of any dietary supplements within 3 months prior to the study; does not smoking or alcohol consumption; does not take any cholesterol; triglyceride as well as blood lowering medicine; does not suffer from any acute condition which needs treatment; does not suffer from metabolic stress, infection or inflammation; does not suffer from abnormal liver or kidney function; without any history of heart disease; does not take estrogen and progesterone; does not suffer from poly cyctic ovarian syndrome; not be pregnant or does not lactating.
Exclusion criteria:; meet any aforementioned condition which can exclude the participants from the study ; present any changes in the diet or physical activity.
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method IL-6. Timepoint: 30 days. Method of measurement: IL-6 was measured by ELISA kits (BioCore, Germany).;MDA. Timepoint: 30 days. Method of measurement: IL-6 was measured by ELISA kits (BioCore, Germany).
- Secondary Outcome Measures
Name Time Method Hs-CRP. Timepoint: 30 days. Method of measurement: ELISA method using using commercial ELISA kit (Biochem, Ontario, Canada).;Glucose. Timepoint: 30 days. Method of measurement: determined through an enzymatic calorimetric method using glucose oxidase by commercial kits (Pars azmoon, Tehran, Iran).;Cholestrol. Timepoint: 30 days. Method of measurement: determined through an enzymatic calorimetric method using glucose oxidase by commercial kits (Pars azmoon, Tehran, Iran).;HDL-C. Timepoint: 30 days. Method of measurement: determined through an enzymatic calorimetric method using glucose oxidase by commercial kits (Pars azmoon, Tehran, Iran).;LDL-C. Timepoint: 30 days. Method of measurement: determined through an enzymatic calorimetric method using glucose oxidase by commercial kits (Pars azmoon, Tehran, Iran).;Insulin. Timepoint: 30 days. Method of measurement: determined through an enzymatic calorimetric method using glucose oxidase by commercial kits (Pars azmoon, Tehran, Iran).